NCT06997588: An ongoing trial by Novartis Pharmaceuticals
This trial is ongoing. It must report results 3 years, 7 months from now.
Full data
| Full entry on ClinicalTrials.gov | NCT06997588 |
|---|---|
| Title | Study Assessing the Efficacy, Safety and Pharmacokinetics of Alpelisib in Pediatric and Adult Patients With PIK3CA-related Overgrowth Spectrum (PROS) |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Oct. 9, 2025 |
| Completion date | Aug. 2, 2028 |
| Required reporting date | Aug. 2, 2029, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |